ALT - Altimmune, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow

Income Statement

Annual
All numbers in thousands
Revenue12/31/201812/31/201712/31/201612/31/2015
Total Revenue10,331.16810,738.3223,236.1754,654.468
Cost of Revenue18,459.3118,406.3297,221.465,063.65
Gross Profit-8,128.142-7,668.007-3,985.285-409.182
Operating Expenses
Research Development----
Selling General and Administrative9,765.5818,457.5576,435.134,880.983
Non Recurring----
Others----
Total Operating Expenses28,224.89126,863.88613,656.599,944.633
Operating Income or Loss-17,893.723-16,125.564-10,420.415-5,290.165
Income from Continuing Operations
Total Other Income/Expenses Net-27,427.223-35,938.201-666.397-1,358.737
Earnings Before Interest and Taxes-17,893.723-16,125.564-10,420.415-5,290.165
Interest Expense-297.09-162.139-38.499-55.305
Income Before Tax-45,320.946-52,063.765-11,086.812-6,648.902
Income Tax Expense-6,149.794-5,638.375--
Minority Interest----
Net Income From Continuing Ops-39,171.152-46,425.39-11,086.812-6,648.902
Non-recurring Events
Discontinued Operations----
Extraordinary Items----
Effect Of Accounting Changes----
Other Items----
Net Income
Net Income-39,171.152-46,425.39-11,086.812-6,648.902
Preferred Stock And Other Adjustments----
Net Income Applicable To Common Shares-42,478.952-51,355.4-11,455.36-6,787.457